Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Monoclonal antibodies (mAbs) Biosimilars market report explains the definition, types, applications, major countries, and major players of the Monoclonal antibodies (mAbs) Biosimilars market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
AET Biotech
Celltrion
Hospira
Allergan
Biocon
Amega Biotech
Accord Healthcare
Dr Reddy's Laboratories
Others
3SBio
By Type:
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
3SBio
By End-User:
Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
3SBio
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
3SBio
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
3SBio
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Monoclonal antibodies (mAbs) Biosimilars Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Monoclonal antibodies (mAbs) Biosimilars Outlook to 2028- Original Forecasts
-
2.2 Monoclonal antibodies (mAbs) Biosimilars Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Monoclonal antibodies (mAbs) Biosimilars Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Monoclonal antibodies (mAbs) Biosimilars Market- Recent Developments
-
6.1 Monoclonal antibodies (mAbs) Biosimilars Market News and Developments
-
6.2 Monoclonal antibodies (mAbs) Biosimilars Market Deals Landscape
7 Monoclonal antibodies (mAbs) Biosimilars Raw Materials and Cost Structure Analysis
-
7.1 Monoclonal antibodies (mAbs) Biosimilars Key Raw Materials
-
7.2 Monoclonal antibodies (mAbs) Biosimilars Price Trend of Key Raw Materials
-
7.3 Monoclonal antibodies (mAbs) Biosimilars Key Suppliers of Raw Materials
-
7.4 Monoclonal antibodies (mAbs) Biosimilars Market Concentration Rate of Raw Materials
-
7.5 Monoclonal antibodies (mAbs) Biosimilars Cost Structure Analysis
-
7.5.1 Monoclonal antibodies (mAbs) Biosimilars Raw Materials Analysis
-
7.5.2 Monoclonal antibodies (mAbs) Biosimilars Labor Cost Analysis
-
7.5.3 Monoclonal antibodies (mAbs) Biosimilars Manufacturing Expenses Analysis
8 Global Monoclonal antibodies (mAbs) Biosimilars Import and Export Analysis (Top 10 Countries)
-
8.1 Global Monoclonal antibodies (mAbs) Biosimilars Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Monoclonal antibodies (mAbs) Biosimilars Export by Region (Top 10 Countries) (2017-2028)
9 Global Monoclonal antibodies (mAbs) Biosimilars Market Outlook by Types and Applications to 2022
-
9.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Erythropoietin (EPO) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Human Growth Hormone (HGH) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Monoclonal Antibody (mAb) Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Insulin Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Interferon (IFN) Consumption and Growth Rate (2017-2022)
-
9.1.7 Global 3SBio Consumption and Growth Rate (2017-2022)
-
9.2 Global Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Anti-Cancer Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Anti-Inflammatory/Autoimmune Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Monoclonal antibodies (mAbs) Biosimilars Market Analysis and Outlook till 2022
-
10.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.2.2 Canada Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.2.3 Mexico Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.2 UK Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.3 Spain Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.4 Belgium Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.5 France Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.6 Italy Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.7 Denmark Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.8 Finland Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.9 Norway Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.10 Sweden Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.11 Poland Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.12 Russia Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.3.13 Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.2 Japan Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.3 India Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.4 South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.5 Pakistan Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.6 Bangladesh Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.7 Indonesia Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.8 Thailand Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.9 Singapore Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.10 Malaysia Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.11 Philippines Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.4.12 Vietnam Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.2 Colombia Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.3 Chile Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.4 Argentina Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.5 Venezuela Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.6 Peru Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.7 Puerto Rico Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.5.8 Ecuador Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.6.2 Kuwait Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.6.3 Oman Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.6.4 Qatar Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.6.5 Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.6.6 United Arab Emirates Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.7.2 South Africa Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.7.3 Egypt Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.7.4 Algeria Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
-
10.8.2 New Zealand Monoclonal antibodies (mAbs) Biosimilars Consumption (2017-2022)
11 Global Monoclonal antibodies (mAbs) Biosimilars Competitive Analysis
-
11.1 AET Biotech
-
11.1.1 AET Biotech Company Details
-
11.1.2 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.1.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Celltrion
-
11.2.1 Celltrion Company Details
-
11.2.2 Celltrion Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Hospira
-
11.3.1 Hospira Company Details
-
11.3.2 Hospira Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.3.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Allergan
-
11.4.1 Allergan Company Details
-
11.4.2 Allergan Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.4.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Biocon
-
11.5.1 Biocon Company Details
-
11.5.2 Biocon Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.5.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Amega Biotech
-
11.6.1 Amega Biotech Company Details
-
11.6.2 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.6.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Accord Healthcare
-
11.7.1 Accord Healthcare Company Details
-
11.7.2 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.7.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Dr Reddy's Laboratories
-
11.8.1 Dr Reddy's Laboratories Company Details
-
11.8.2 Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.8.4 Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Others
-
11.9.1 Others Company Details
-
11.9.2 Others Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Others Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.9.4 Others Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 3SBio
-
11.10.1 3SBio Company Details
-
11.10.2 3SBio Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
11.10.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Monoclonal antibodies (mAbs) Biosimilars Market Outlook by Types and Applications to 2028
-
12.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Erythropoietin (EPO) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Human Growth Hormone (HGH) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Monoclonal Antibody (mAb) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Insulin Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Interferon (IFN) Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global 3SBio Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Anti-Cancer Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Anti-Inflammatory/Autoimmune Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Monoclonal antibodies (mAbs) Biosimilars Market Analysis and Outlook to 2028
-
13.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.2.2 Canada Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.2.3 Mexico Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.2 UK Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.3 Spain Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.4 Belgium Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.5 France Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.6 Italy Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.7 Denmark Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.8 Finland Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.9 Norway Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.10 Sweden Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.11 Poland Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.12 Russia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.3.13 Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.2 Japan Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.3 India Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.4 South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.8 Thailand Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.9 Singapore Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.11 Philippines Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.2 Colombia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.3 Chile Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.4 Argentina Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.6 Peru Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.6.3 Oman Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.6.4 Qatar Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.7.2 South Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.7.3 Egypt Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.7.4 Algeria Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Monoclonal antibodies (mAbs) Biosimilars
-
Figure of Monoclonal antibodies (mAbs) Biosimilars Picture
-
Table Global Monoclonal antibodies (mAbs) Biosimilars Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Monoclonal antibodies (mAbs) Biosimilars Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Erythropoietin (EPO) Consumption and Growth Rate (2017-2022)
-
Figure Global Human Growth Hormone (HGH) Consumption and Growth Rate (2017-2022)
-
Figure Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption and Growth Rate (2017-2022)
-
Figure Global Monoclonal Antibody (mAb) Consumption and Growth Rate (2017-2022)
-
Figure Global Insulin Consumption and Growth Rate (2017-2022)
-
Figure Global Interferon (IFN) Consumption and Growth Rate (2017-2022)
-
Figure Global 3SBio Consumption and Growth Rate (2017-2022)
-
Figure Global Anti-Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Anti-Inflammatory/Autoimmune Consumption and Growth Rate (2017-2022)
-
Figure Global Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Table North America Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure United States Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Canada Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Mexico Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table Europe Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure Germany Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure UK Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Spain Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Belgium Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure France Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Italy Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Denmark Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Finland Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Norway Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Sweden Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Poland Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Russia Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table APAC Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Japan Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure India Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Thailand Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Singapore Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Philippines Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table South America Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure Brazil Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Colombia Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Chile Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Argentina Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Peru Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table GCC Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure Bahrain Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Oman Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Qatar Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table Africa Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure Nigeria Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure South Africa Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Egypt Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure Algeria Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table Oceania Monoclonal antibodies (mAbs) Biosimilars Consumption by Country (2017-2022)
-
Figure Australia Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Monoclonal antibodies (mAbs) Biosimilars Consumption and Growth Rate (2017-2022)
-
Table AET Biotech Company Details
-
Table AET Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table AET Biotech Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Celltrion Company Details
-
Table Celltrion Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celltrion Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Celltrion Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Hospira Company Details
-
Table Hospira Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Hospira Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Hospira Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Allergan Company Details
-
Table Allergan Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Allergan Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Biocon Company Details
-
Table Biocon Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biocon Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Biocon Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Amega Biotech Company Details
-
Table Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Accord Healthcare Company Details
-
Table Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Dr Reddy's Laboratories Company Details
-
Table Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Dr Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table Others Company Details
-
Table Others Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table Others Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table Others Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Table 3SBio Company Details
-
Table 3SBio Monoclonal antibodies (mAbs) Biosimilars Sales, Price, Value and Gross Profit (2017-2022)
-
Table 3SBio Monoclonal antibodies (mAbs) Biosimilars Main Business and Markets Served
-
Table 3SBio Monoclonal antibodies (mAbs) Biosimilars Product Portfolio
-
Figure Global Erythropoietin (EPO) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Human Growth Hormone (HGH) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Granulocyte- Colony Stimulating Factor (G-CSF) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monoclonal Antibody (mAb) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Insulin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Interferon (IFN) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global 3SBio Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Anti-Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Anti-Inflammatory/Autoimmune Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Table North America Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure United States Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure Germany Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure China Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure Brazil Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast by Country (2022-2028)
-
Figure Australia Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Monoclonal antibodies (mAbs) Biosimilars Consumption Forecast and Growth Rate (2022-2028)
-
